Prevention of chronic HBsAg carrier state in infants of HBsAg-positive mothers by hepatitis B immunoglobulin.
21 children of HBsAg-carrier mothers were given 0.5 ml/kg hepatitis B immunoglobulin (HBIg) within 48 h after birth and subsequently 0.16 ml/kg every month for 6 months; 20 children were not treated. None of the HBIg-treated children became HBsAg positive, compared with 5 of the untreated children (p less than 0.02). 2 of 3 children who were not started on HBIg until the fourth or fifth day after birth also became HBsAg positive. 4 children of mothers who had acute hepatitis B in the third trimester of pregnancy were treated with HBIg and remained HBsAg negative, whereas another, untreated, child became HBsAg positive.
D000914:Antibodies, Viral / Q000008:administration & dosage*; D002353:Carrier State / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000517:prevention & control* / Q000635:transmission; D006510:Hepatitis B Antibodies / Q000008:administration & dosage*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000635:transmission; D013997:Time Factors
D000914:Antibodies, Viral; D006510:Hepatitis B Antibodies; D007136:Immunoglobulins